195 related articles for article (PubMed ID: 38054800)
1. Treatment of Severe Palmoplantar Pustular Psoriasis With Bimekizumab.
Passeron T; Perrot JL; Jullien D; Goujon C; Ruer M; Boyé T; Villani AP; Quiles Tsimaratos N
JAMA Dermatol; 2024 Feb; 160(2):199-203. PubMed ID: 38054800
[TBL] [Abstract][Full Text] [Related]
2. Tofacitinib for the Treatment of Nail Lesions and Palmoplantar Pustulosis in Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis Syndrome.
Li C; Li Z; Cao Y; Li L; Li F; Li Y; Xiong D; Wu X; Zhang W; Zeng X
JAMA Dermatol; 2021 Jan; 157(1):74-78. PubMed ID: 32997094
[TBL] [Abstract][Full Text] [Related]
3. Interventions for chronic palmoplantar pustulosis.
Obeid G; Do G; Kirby L; Hughes C; Sbidian E; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011628. PubMed ID: 31958161
[TBL] [Abstract][Full Text] [Related]
4. A brief guide to pustular psoriasis for primary care providers.
Crowley JJ; Pariser DM; Yamauchi PS
Postgrad Med; 2021 Apr; 133(3):330-344. PubMed ID: 33118424
[TBL] [Abstract][Full Text] [Related]
5. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
[TBL] [Abstract][Full Text] [Related]
6. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
8. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
9. Clinical Characteristics of Japanese Patients with Palmoplantar Pustulosis.
Yamamoto T
Clin Drug Investig; 2019 Mar; 39(3):241-252. PubMed ID: 30632109
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Biologic Therapy for the Management of Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review.
Sanchez IM; Sorenson E; Levin E; Liao W
Dermatol Ther (Heidelb); 2017 Dec; 7(4):425-446. PubMed ID: 29143230
[TBL] [Abstract][Full Text] [Related]
11. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
12. Acrodermatitis continua of Hallopeau successfully treated with bimekizumab: A case report.
Cirone KD; Lovegrove FE
SAGE Open Med Case Rep; 2023; 11():2050313X231160937. PubMed ID: 36968989
[TBL] [Abstract][Full Text] [Related]
13. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
14. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
[TBL] [Abstract][Full Text] [Related]
15. Demographic, clinical, and scintigraphic comparison of patients affected by palmoplantar pustulosis and severe acne: a retrospective study.
Li Y; Li C; Wu N; Li F; Wu Z; Sun X; Li Q; Li L
Clin Rheumatol; 2020 Jun; 39(6):1989-1996. PubMed ID: 31953569
[TBL] [Abstract][Full Text] [Related]
16. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study.
Brunasso AM; Puntoni M; Aberer W; Delfino C; Fancelli L; Massone C
Br J Dermatol; 2013 Jun; 168(6):1243-51. PubMed ID: 23301847
[TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.
Wollina U; Hansel G; Koch A; Schönlebe J; Köstler E; Haroske G
Am J Clin Dermatol; 2008; 9(1):1-14. PubMed ID: 18092839
[TBL] [Abstract][Full Text] [Related]
18. Spesolimab Efficacy and Safety in Patients with Moderate-to-Severe Palmoplantar Pustulosis: A Multicentre, Double-Blind, Randomised, Placebo-Controlled, Phase IIb, Dose-Finding Study.
Burden AD; Bissonnette R; Navarini AA; Murakami M; Morita A; Haeufel T; Ye B; Baehner F; Terui T
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2279-2297. PubMed ID: 37731086
[TBL] [Abstract][Full Text] [Related]
19. Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis.
Huang IH; Wu PC; Chiu HY; Huang YH
Am J Clin Dermatol; 2024 May; 25(3):347-358. PubMed ID: 38438782
[TBL] [Abstract][Full Text] [Related]
20. SAPHO Syndrome with Palmoplantar Pustulosis as the First Manifestation Successfully Treated with Adalimumab.
Yang Q; Xiang T; Wu Y; Ye E; He B; Bu Z
Clin Cosmet Investig Dermatol; 2022; 15():2547-2554. PubMed ID: 36466944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
